Ines Ben Ayed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ines Ben Ayed has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Afifa Maaloul
Department of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunis, Tunisia
1 shared publication- Afifa Maaloul
Department of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunis 1002, Tunisia
1 shared publication Amira Jaballah
Department of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunis, Tunisia
1 shared publication- Amira Jaballah-Gabteni
Department of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunis 1002, Tunisia
1 shared publication Haifa Tounsi
Department of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunis, Tunisia
1 shared publication- Haifa Tounsi Kettiti
Department of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunis 1002, Tunisia
1 shared publication
Latest Publications
- Open Access
- 27 June 2019
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 17 (1) , 1-13
Identification of novel pathogenic MSH2 mutation and new DNA repair genes variants: investigation of a Tunisian Lynch syndrome family with discordant twins
Lynch syndrome (LS) is a highly penetrant inherited cancer predisposition syndrome, characterized by autosomal dominant inheritance and germline mutations in DNA mismatch repair genes. Despite several genetic variations that have been identified in various populations, the penetrance is highly variable and the reasons for this have not been fully elucidated. This study investigates whether, besides pathogenic mutations, environment and low penetrance genetic risk factors may result in phenotype modification in a Tunisian LS family. A Tunisian family with strong colorectal cancer (CRC) history that fulfill the Amsterdam I criteria for the diagnosis of Lynch syndrome was proposed for oncogenetic counseling. The index case was a man, diagnosed at the age of 33 years with CRC. He has a monozygotic twin diagnosed at the age of 35 years with crohn disease. Forty-seven years-old was the onset age of his paternal uncle withCRC. An immunohistochemical (IHC) labeling for the four proteins (MLH1, MSH2, MSH6 and PMS2) of the MisMatchRepair (MMR) system was performed for the index case. A targeted sequencing of MSH2, MLH1 and a panel of 85 DNA repair genes was performed for the index case and for his unaffected father. The IHC results showed a loss of MSH2 but not MLH1, MSH6 and PMS2 proteins expression. Genomic DNA screening, by targeted DNA repair genes sequencing, revealed an MSH2 pathogenic mutation (c.1552C>T; p.Q518X), confirmed by Sanger sequencing. This mutation was suspected to be a causal mutation associated to the loss of MSH2 expression and it was found in first and second degree relatives. The index case has smoking and alcohol consumption habits. Moreover, he harbors extensive genetic variations in other DNA-repair genes not shared with his unaffected father. In our investigated Tunisian family, we confirmed the LS by IHC, molecular and in silico investigations. We identified a novel pathogenic mutation described for the first time in Tunisia. These results come enriching the previously reported pathogenic mutations in LS families. Our study brings new arguments to the interpretation of MMR expression pattern and highlights new risk modifiers genes eventually implicated in CRC. Twins discordance reported in this work underscore that disease penetrance could be influenced by both genetic background and environmental factors.
- 27 June 2019
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 17 (1) , 1-13
Open AccessIdentification of novel pathogenic MSH2 mutation and new DNA repair genes variants: investigation of a Tunisian Lynch syndrome family with discordant twins
Lynch syndrome (LS) is a highly penetrant inherited cancer predisposition syndrome, characterized by autosomal dominant inheritance and germline mutations in DNA mismatch repair genes. Despite several genetic variations that have been identified in various populations, the penetrance is highly variable and the reasons for this have not been fully elucidated. This study investigates whether, besides pathogenic mutations, environment and low penetrance genetic risk factors may result in phenotype modification in a Tunisian LS family. A Tunisian family with strong colorectal cancer (CRC) history that fulfill the Amsterdam I criteria for the diagnosis of Lynch syndrome was proposed for oncogenetic counseling. The index case was a man, diagnosed at the age of 33 years with CRC. He has a monozygotic twin diagnosed at the age of 35 years with crohn disease. Forty-seven years-old was the onset age of his paternal uncle withCRC. An immunohistochemical (IHC) labeling for the four proteins (MLH1, MSH2, MSH6 and PMS2) of the MisMatchRepair (MMR) system was performed for the index case. A targeted sequencing of MSH2, MLH1 and a panel of 85 DNA repair genes was performed for the index case and for his unaffected father. The IHC results showed a loss of MSH2 but not MLH1, MSH6 and PMS2 proteins expression. Genomic DNA screening, by targeted DNA repair genes sequencing, revealed an MSH2 pathogenic mutation (c.1552C>T; p.Q518X), confirmed by Sanger sequencing. This mutation was suspected to be a causal mutation associated to the loss of MSH2 expression and it was found in first and second degree relatives. The index case has smoking and alcohol consumption habits. Moreover, he harbors extensive genetic variations in other DNA-repair genes not shared with his unaffected father. In our investigated Tunisian family, we confirmed the LS by IHC, molecular and in silico investigations. We identified a novel pathogenic mutation described for the first time in Tunisia. These results come enriching the previously reported pathogenic mutations in LS families. Our study brings new arguments to the interpretation of MMR expression pattern and highlights new risk modifiers genes eventually implicated in CRC. Twins discordance reported in this work underscore that disease penetrance could be influenced by both genetic background and environmental factors.
- 11 April 2019
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 46 (8) , 591-598
Mucosal human papillomavirus detection and TP53 immunohistochemical expression in non‐melanoma skin cancer in Tunisian patients
Background Several studies have reported the oncogenic role of human papillomavirus (HPV) in non ‐melanoma skin cancer (NMSC) carcinogenesis. Considering that HPV could affect TP53 degradation via E6 oncoprotein, we evaluated the expression of TP53 according to HPV infection and E6 expression. Methods Biopsy specimens from 79 NMSCs (28 squamous cell carcinomas, 21 keratoacanthomas and 30 basal cell carcinomas) were enrolled. Nested PCR was used to detect mucosal HPV (mHPV) DNA. Genotyping was performed by reverse line hybridization. Expression of TP53 and E6 was evaluated by immunohistochemistry. Results mHPVs were detected in 34.2% (27/79) of NMSC, with 92.6% (25/27) of high‐risk HPV (HR‐HPV) types. HPV16‐E6‐positive expression was observed in all HPV16‐positive samples. TP53 high expression was found in 51.4% (37/72) of specimens. In this group, 78.4% were HPV‐negative (p = 0.014). TP53 expression was negative in 8/10 of HPV E6‐positive specimens. Multivariate analysis showed that TP53 was associated with HPV infection independently of histopathologic type (p = 0.005). Conclusions This study showed a high prevalence of mHPV in NMSC. Active infections assessed by E6 expression are associated with loss of p53 function, highlighting the involvement of mHPV in NMSC carcinogenesis.
- 11 April 2019
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 46 (8) , 591-598
Mucosal human papillomavirus detection and TP53 immunohistochemical expression in non‐melanoma skin cancer in Tunisian patients
Background Several studies have reported the oncogenic role of human papillomavirus (HPV) in non ‐melanoma skin cancer (NMSC) carcinogenesis. Considering that HPV could affect TP53 degradation via E6 oncoprotein, we evaluated the expression of TP53 according to HPV infection and E6 expression. Methods Biopsy specimens from 79 NMSCs (28 squamous cell carcinomas, 21 keratoacanthomas and 30 basal cell carcinomas) were enrolled. Nested PCR was used to detect mucosal HPV (mHPV) DNA. Genotyping was performed by reverse line hybridization. Expression of TP53 and E6 was evaluated by immunohistochemistry. Results mHPVs were detected in 34.2% (27/79) of NMSC, with 92.6% (25/27) of high‐risk HPV (HR‐HPV) types. HPV16‐E6‐positive expression was observed in all HPV16‐positive samples. TP53 high expression was found in 51.4% (37/72) of specimens. In this group, 78.4% were HPV‐negative (p = 0.014). TP53 expression was negative in 8/10 of HPV E6‐positive specimens. Multivariate analysis showed that TP53 was associated with HPV infection independently of histopathologic type (p = 0.005). Conclusions This study showed a high prevalence of mHPV in NMSC. Active infections assessed by E6 expression are associated with loss of p53 function, highlighting the involvement of mHPV in NMSC carcinogenesis.